PHN Stock Overview
A pharmaceutical and nutraceutical company, researches, designs, develops, and markets nutritional supplements and medical devices in Italy, Europe, the Middle East, South America, Far East, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 5/6 |
| Past Performance | 3/6 |
| Financial Health | 5/6 |
| Dividends | 2/6 |
Rewards
Risk Analysis
PHN passed our risk checks.
Pharmanutra S.p.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €58.20 |
| 52 Week High | €63.50 |
| 52 Week Low | €44.85 |
| Beta | 0.31 |
| 11 Month Change | 1.22% |
| 3 Month Change | 23.44% |
| 1 Year Change | 18.41% |
| 33 Year Change | -13.13% |
| 5 Year Change | 183.90% |
| Change since IPO | 316.01% |
Recent News & Updates
Investors Interested In Pharmanutra S.p.A.'s (BIT:PHN) Earnings
Sep 11
Pharmanutra's (BIT:PHN) Shareholders Have More To Worry About Than Only Soft Earnings
Mar 23Recent updates
Investors Interested In Pharmanutra S.p.A.'s (BIT:PHN) Earnings
Sep 11Pharmanutra's (BIT:PHN) Shareholders Have More To Worry About Than Only Soft Earnings
Mar 23Is Now The Time To Put Pharmanutra (BIT:PHN) On Your Watchlist?
Sep 26These 4 Measures Indicate That Pharmanutra (BIT:PHN) Is Using Debt Safely
May 16Pharmanutra (BIT:PHN) Could Easily Take On More Debt
Jan 11Capital Allocation Trends At Pharmanutra (BIT:PHN) Aren't Ideal
Nov 02Pharmanutra (BIT:PHN) Will Be Hoping To Turn Its Returns On Capital Around
Aug 03Is Now The Time To Put Pharmanutra (BIT:PHN) On Your Watchlist?
May 20Returns On Capital Signal Tricky Times Ahead For Pharmanutra (BIT:PHN)
Apr 19Are Strong Financial Prospects The Force That Is Driving The Momentum In Pharmanutra S.p.A.'s BIT:PHN) Stock?
Mar 10Is There More To The Story Than Pharmanutra's (BIT:PHN) Earnings Growth?
Feb 17
Should You Be Adding Pharmanutra (BIT:PHN) To Your Watchlist Today?
Feb 01Is Pharmanutra S.p.A. (BIT:PHN) A Smart Choice For Dividend Investors?
Jan 18Is Pharmanutra (BIT:PHN) A Risky Investment?
Jan 04Shareholders Of Pharmanutra (BIT:PHN) Must Be Happy With Their 220% Total Return
Dec 22Do Insiders Own Lots Of Shares In Pharmanutra S.p.A. (BIT:PHN)?
Dec 08Is Pharmanutra S.p.A.'s(BIT:PHN) Recent Stock Performance Tethered To Its Strong Fundamentals?
Nov 23Shareholder Returns
| PHN | IT Personal Products | IT Market | |
|---|---|---|---|
| 7D | 1.4% | -2.7% | 2.1% |
| 1Y | 18.4% | 7.5% | 24.2% |
Return vs Industry: PHN exceeded the Italian Personal Products industry which returned 7.5% over the past year.
Return vs Market: PHN underperformed the Italian Market which returned 24.2% over the past year.
Price Volatility
| PHN volatility | |
|---|---|
| PHN Average Weekly Movement | 4.6% |
| Personal Products Industry Average Movement | 3.9% |
| Market Average Movement | 4.1% |
| 10% most volatile stocks in IT Market | 6.9% |
| 10% least volatile stocks in IT Market | 2.5% |
Stable Share Price: PHN has not had significant price volatility in the past 3 months compared to the Italian market.
Volatility Over Time: PHN's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 112 | Roberto Lacorte | www.pharmanutra.it |
Pharmanutra S.p.A., a pharmaceutical and nutraceutical company, researches, designs, develops, and markets nutritional supplements and medical devices in Italy, Europe, the Middle East, South America, Far East, and internationally. It also produces and markets pharmaceuticals, medical devices, OTC products, and nutraceuticals for pediatric sector; and produces and distributes raw materials and active ingredients for the food, pharmaceutical, and food supplement industries. The company’s products primarily include SiderAL, SiderAL Forte, SiderAL Folic, Cardio SiderAL, SiderAL Med, Cetilar Crema, Cetilar Patch, Cetilar Tape, Cetilar Oro, Cetilar Nutrition, ApportAL, UltraMag, Gestalys DHA, Novomega, Bonecal, and DiKappa 2.
Pharmanutra S.p.A. Fundamentals Summary
| PHN fundamental statistics | |
|---|---|
| Market cap | €559.18m |
| Earnings (TTM) | €14.50m |
| Revenue (TTM) | €107.61m |
38.6x
P/E Ratio5.2x
P/S RatioIs PHN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PHN income statement (TTM) | |
|---|---|
| Revenue | €107.61m |
| Cost of Revenue | €54.85m |
| Gross Profit | €52.76m |
| Other Expenses | €38.26m |
| Earnings | €14.50m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.51 |
| Gross Margin | 49.03% |
| Net Profit Margin | 13.47% |
| Debt/Equity Ratio | 47.1% |
How did PHN perform over the long term?
See historical performance and comparison